February 18, 2026 7:49am

The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when markets and the C&GT sector act like it’s their blueprint

Minutes and coming econs, waiting for Fed minutes from the policymakers’ January and the (PCE) personal consumption expenditure price index reading due on Friday

Pre-open Signals: 3 Positive and 1 Negative; if you understand probabilities, the inevitable is easier to maneuver

News: Moderna (MRNA +$1.41 or +3.21% pre-open) announced that, in response to a prior Refusal-to-File (RTF) letter, the MRNA has engaged with the FDA in a Type A meeting and proposed a revised regulatory approach for its investigational seasonal influenza vaccine candidate, mRNA-1010. To advance the review, Moderna proposed a regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults.

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t! 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

RMi Closing Bell: Sector share pricing on a tear … https://www.regmedinvestors.com/articles/14316

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The pre-open Dow futures are UP +0.09% or (+44 points), the S&P futures are UP +0.28% or (+19 points) and the Nasdaq futures are UP +0.37% or (+91 points)

  • U.S. stock futures are on the move up, Wednesday, 2/18
  • European markets are rising,
  • Asia Pacific are also on the rise

Economic Data: Empire State manufacturing survey - Feb. and Home builder confidence index

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed UP +32.26 points or +0.07%, the S&P closed UP +7.05 points or +0.10% while the Nasdaq closed UP +31.713 points or +0.14%
  • Monday was holiday
  • Friday: The Dow closed UP +48.95 points or +0.10%, the S&P closed UP +3.41 points or +0.05% while the Nasdaq closed DOWN -50.4777 points or -0.22%
  • Last week: The S&P 500 was down -1.4%, the Dow -1.2% and the Nasdaq was down -2.1%.
  • The previous week: The S&P 500 closed down -0.1%, the Nasdaq fell -1.84% and the Dow rose +2.5%
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 February – 1 market holiday, 5 positive and 6 negative closes

  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4:

  • December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings coming as sector releases Qs and FY25 …

Looking positive/negative in the pre-open:

BioNTech (BNTX) +$0.23 or +0.21% pre-open

UniQure NV (QURE) +$0.75 or +3.45% pre-open

Moderna (MRNA) +$1.41 or +3.21% pre-open

IQVIA Holdings (IQV) -$0.05 or -0.03% pre-open

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Investors will look for further insight into inflation this week with the release of the Personal Consumption Expenditures index (PCI), scheduled for release Friday.

Are the dice … hot, as they say it is a “crap shoot”        

 

The Q4 and FY25 earnings reporting cycle ….

  • Tuesday - 2/24 – AxoGen (AXGN) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Vericel (VCEL) and BioLife Solutions (BLFS)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

February – 3rd week

  • 2/17 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 2/16 – Monday was market holiday

February – 2nd week

  • 2/13 - Friday closed positive with 24 incliners, 114 decliners and 2 flat
  • 2/12 – Thursday closed negative with 7 incliners, 33 decliners and 2 flats
  • 2/11 - Wednesday closed negative with 12 incliners, 25 decliners and 3 flats
  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 - Monday closed positive with 23 incliners, 14 decliners and 3 flats

February began …

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat
  • 2/3 - Tuesday closed negative with 18 incliners, 21 decliners and 1 flat   
  • 2/2 - Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.